Skip to Content

Join the 'Ameluz' group to help and get support from people like you.

Ameluz News

Biofrontera Announces U.S. FDA Approval of Ameluz and Activating BF-RhodoLED Device for Treatment of Actinic Keratosis

Posted 8 Jun 2016 by Drugs.com

Leverkusen, Germany, May 11, 2016 – Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of its combination topical prescription drug Ameluz (BF-200 ALA) and medical device BF-RhodoLED® for photodynamic therapy (PDT) treatment of mild to moderate actinic keratosis (AK) on the fa ...

Ask a Question

Further Information

Related Condition Support Groups

Actinic Keratosis

Ameluz Patient Information at Drugs.com